NAVigate-ULTRANCT07925359
The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation
StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Incidence of device-related or procedure-related events of a serious nature
Timeframe: Day 0 (ablation procedure) - Day 7; Day 0 - Day 30; Day 0 - Day 60
Acute Procedural Success for PV and LAPW Isolation
Timeframe: At the end of the ablation procedure
Acute Procedural Success for CTI, MI and SVC Ablation
Timeframe: At the end of the ablation procedure
Acute Procedural Success - Timing
Timeframe: At the end of the ablation procedure
Arms and interventions
Treatment Group: Ablation ProcedureOther
Up to approximately 200 subjects scheduled to undergo catheter-based endocardial mapping and ablation in the treatment of paroxysmal or persistent atrial fibrillation (de novo or redo subject) with the new and modified components of the FARAPULSE™ Pulsed Field Ablation (PFA) System when used with the OPAL HDx™ Mapping System.
Devices: Ablation Treatment with FARAPULSE™ Pulsed Field Ablation (PFA) System and OPAL HDx™ Mapping System
Sites
3 sites in 3 countries
Croatia 1, Czechia 1, France 1